Full name: Mirjam De Vries
Current country: Sweden
Membership level: Full
Type of membership: Member
Number of publications: 12
Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study (2018)
https://pubmed.ncbi.nlm.nih.gov/29195024/
C-reactive protein polymorphisms influence serum CRP-levels independent of disease activity in ankylosing spondylitis (2015)
https://pubmed.ncbi.nlm.nih.gov/25603416/
The relationship between disease-related characteristics and conduction disturbances in ankylosing spondylitis (2010)
https://pubmed.ncbi.nlm.nih.gov/20132069/
Discovertebral (Andersson) lesions in severe ankylosing spondylitis: a study using MRI and conventional radiography (2010)
https://pubmed.ncbi.nlm.nih.gov/20496041/
pANCA, ASCA, and OmpC antibodies in patients with ankylosing spondylitis without inflammatory bowel disease (2010)
https://pubmed.ncbi.nlm.nih.gov/20810508/
Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation (2009)
https://pubmed.ncbi.nlm.nih.gov/19822712/
Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis (2009)
https://pubmed.ncbi.nlm.nih.gov/18375542/
Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis (2009)
https://pubmed.ncbi.nlm.nih.gov/19877087/
Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: a prospective cohort study in ankylosing spondylitis (2009)
https://pubmed.ncbi.nlm.nih.gov/19404933/
Discovertebral (Andersson) lesions of the spine in ankylosing spondylitis revisited (2009)
https://pubmed.ncbi.nlm.nih.gov/19294478/
Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation (2007)
https://pubmed.ncbi.nlm.nih.gov/17178760/
Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation (2007)
https://pubmed.ncbi.nlm.nih.gov/17472991/